Advertisement
AZN or LLY or MRK
AZN in upward trend: 10-day moving average moved above 50-day moving average on October 21, 2026
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 51 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 27 of 42 cases over the following month. The odds of a continued upward trend are 64%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.753) is normal, around the industry mean (-1.619). P/E Ratio (27.682) is within average values for comparable stocks, (21.766). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
LLY in upward trend: 10-day moving average moved above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 53 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 231 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.123) is slightly higher than the industry average of (-1.619). P/E Ratio (47.269) is within average values for comparable stocks, (21.766). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
MRK sees its Stochastic Oscillator ascending out of oversold territory
On October 30, 2026, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 37 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on MRK as a result. In 52 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 50 cases over the following month. The odds of a continued upward trend are 54%.
MRK moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 174 of 265 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.729) is normal, around the industry mean (-1.476). MRK's P/E Ratio (117.746) is considerably higher than the industry average of (21.871). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
AZN | LLY | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 42 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 88 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | 5 | 30 | |
SMR RATING 1..100 | 44 | 14 | 79 | |
PRICE GROWTH RATING 1..100 | 36 | 3 | 11 | |
P/E GROWTH RATING 1..100 | 59 | 38 | 1 | |
SEASONALITY SCORE 1..100 | 21 | 21 | 11 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (63) in the Pharmaceuticals Major industry is in the same range as LLY (88) and is in the same range as MRK (88). This means that AZN's stock grew similarly to LLY’s and similarly to MRK’s over the last 12 months.
LLY's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as AZN (14) and is in the same range as MRK (30). This means that LLY's stock grew similarly to AZN’s and similarly to MRK’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as AZN (44) and is somewhat better than the same rating for MRK (79). This means that LLY's stock grew similarly to AZN’s and somewhat faster than MRK’s over the last 12 months.
LLY's Price Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as MRK (11) and is somewhat better than the same rating for AZN (36). This means that LLY's stock grew similarly to MRK’s and somewhat faster than AZN’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (38) and is somewhat better than the same rating for AZN (59). This means that MRK's stock grew somewhat faster than LLY’s and somewhat faster than AZN’s over the last 12 months.
| AZN | LLY | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 43% | 1 day ago 62% | N/A |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 53% | 2 days ago 71% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 65% | 2 days ago 61% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 84% | 2 days ago 54% |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 70% | 2 days ago 57% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 69% | 2 days ago 57% |
| Advances ODDS (%) | 5 days ago 57% | 5 days ago 70% | 5 days ago 57% |
| Declines ODDS (%) | 1 day ago 46% | 1 day ago 54% | 9 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 46% | 1 day ago 50% | 2 days ago 63% |
| Aroon ODDS (%) | N/A | 1 day ago 78% | 2 days ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 1 FA rating(s) are green while LLY’s FA Score has 3 green FA rating(s), and MRK’s FA Score reflects 3 green FA rating(s).
- AZN’s FA Score: 1 green, 4 red.
- LLY’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s), and MRK’s TA Score reflects 7 bullish TA indicator(s).
- AZN’s TA Score: 5 bullish, 4 bearish.
- LLY’s TA Score: 6 bullish, 4 bearish.
- MRK’s TA Score: 7 bullish, 2 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а +8.11% price change this week, while LLY (@Pharmaceuticals: Major) price change was +9.94% , and MRK (@Pharmaceuticals: Major) price fluctuated +5.51% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.32%. For the same industry, the average monthly price growth was -0.80%, and the average quarterly price growth was +3.89%.
Reported Earning Dates
AZN is expected to report earnings on Feb 11, 2027.
LLY is expected to report earnings on Feb 10, 2027.
MRK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.32% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -2.49% | ||
| GSK - MRK | 50% Loosely correlated | -0.88% | ||
| JNJ - MRK | 48% Loosely correlated | -1.62% | ||
| AMGN - MRK | 47% Loosely correlated | -0.90% | ||
| NVS - MRK | 47% Loosely correlated | -1.40% | ||
| BIIB - MRK | 46% Loosely correlated | -0.03% | ||
More | ||||